- Home
- INO vs CHMI Comparison
INO vs CHMI Comparison
Compare INO & CHMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INO | CHMI |
|---|---|---|
| Founded | 1979 | 2012 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Medical/Dental Instruments | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 93.0M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | INO | CHMI |
|---|---|---|
| Price | $1.15 | $2.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $6.75 | $3.00 |
| AVG Volume (30 Days) | ★ 2.9M | 207.7K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 15.15% |
| EPS Growth | ★ 54.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $42,220,086.00 | N/A |
| Revenue This Year | $20,156.19 | N/A |
| Revenue Next Year | $421.95 | $61.13 |
| P/E Ratio | ★ N/A | $139.30 |
| Revenue Growth | ★ 19.37 | N/A |
| 52 Week Low | $1.03 | $2.17 |
| 52 Week High | $2.86 | $3.14 |
Technical Indicators
Market Signals| Indicator | INO | CHMI |
|---|---|---|
| Relative Strength Index (RSI) | 36.14 | 51.67 |
| Support Level | $1.03 | $2.52 |
| Resistance Level | $1.56 | $2.67 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 15.33 | 85.00 |
Price Performance
Historical ComparisonAbout INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About CHMI Cherry Hill Mortgage Investment Corporation
Cherry Hill Mortgage Investment Corp is a fully integrated, internally managed residential real estate finance company focused on acquiring, investing in and managing residential mortgage assets in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.